| abstract |
K ATP channel openers such as diazoxide that achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional results in the treatment of diseases or disorders involving KATP channels Immediate or long-term administration of a particular salt of the subject to a subject is provided. Also provided are methods of pharmaceutical formulation, administration and dosing of salts that achieve these results and reduce the incidence of adverse effects in the treated individual. Further provided are methods of treating human and animal diseases by co-administering their salts and other agents. [Selection] Figure 1 |